27
Apr
2011
24
Feb
2011
Posted in I - Series E, Q - 1Q11, R - WEST, X - AMD, X - Device (Ophthalmology), XX - CA
VisionCare Ophthalmic Technologies (Saratoga, CA) a commercial-stage medical device company focused on advanced age-related macular degeneration, closed a $31M Series E financing. Participants include Saints Venture Capital, Giza Ventures, Generali Financial Holdings, BSI, Pitango Venture Capital, Three Arch Partners, Onset Ventures and Infinity CSVC Management.
18
Jan
2011
19
Oct
2010
27
Aug
2010
Posted in I - Series E, Q - 3Q10, R - WEST, X - Device (Sequencing), XX - CA
Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.
24
Aug
2010
Posted in I - Series E, Q - 3Q10, R - NORTH EAST, X - Oncology, XX - PA
Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.
16
Jul
2010
25
Jun
2010
Posted in I - Series E, Q - 2Q10, R - WEST, X - Oncology, XX - CA
Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.
07
Jun
2010
Posted in I - Series E, Q - 2Q10, R - MID WEST, X - Device (Spine), XX - MN
Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $18.3M Series E financing. Participants include Hatteras Late Stage VC Fund, Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
12
Apr
2010
Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO
GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]
06
Apr
2010
30
Mar
2010
Posted in I - Series E, Q - 1Q10, R - NORTH EAST, X - Device (Organ Transplant), XX - MA
TransMedics (Andover, MA) a clinical-stage medical device company focused on a technology platform to maintain donor organs in near-physiologic and functioning condition during transport for organ transplantation, closed a $36M Series E financing. Participants include Foundation Capital, Kleiner Perkins Caufield & Byers, Flagship Ventures, 3i Group, Tudor Investment, VantagePoint Venture Partners, Sherbrooke Partners, Alta Partners, [...]
04
Mar
2010
Posted in I - Series E, Q - 1Q10, R - NORTH EAST, X - TeleMedicine, XX - NJ
ImpactRx (Mt. Laurel, NJ) a commercial-stage provider of online content measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation’s highest value physicians, closed a $1.2M Series E financing. Participants have included Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck.